Research and Development
Neos Therapeutics has developed proprietary drug delivery technologies that enable the creation of stable controlled release (CR) products; CR liquids and CR oral disintegrating tablets (ODTs), with suitable flavors and mouth feel.
Neos' technology can provide a customized release profile and accommodate the need for a variety of release profiles including the combination of IR and CR profiles for a single active ingredient or a combination of active compounds.
The Neos technology platform leverages a drug/resin complex to create controlled release Rx or OTC products in convenient oral liquid and ODT dosage forms to better serve patients that experience difficulty swallowing oral solid forms, benefit from titration flexibility, or prefer the portability of ODTs.
Liquid Technology: Dynamic Time Release Suspension® (DTRS®)
- Coated ion exchange resin creates a commercially stable sustained release suspension
- Multiple drug-release profiles include delayed, first and second-order release
- Taste-masking covers bitter or harsh tastes
- Excellent product reproducibility, uniformity and shelf life
- Dosing convenience and titration flexibility may increase patient adherence
ODT Technology: Rapidly Disintegrating Ionic Masking™ (RDIM™)
- Coated ion exchange resin creates a sustained release orally disintegrating tablet
- Taste-masking covers bitter or harsh tastes
- Excellent product reproducibility, uniformity, and shelf life
- Dosing convenience may increase patient adherence
|
